Listed by the USPTO as KOMATSU, LI N
Tech Center 1600 • Art Units: 1654 1658 1676
This examiner grants 60% of resolved cases
KOMATSU, LI N handles cases in tech center 1600 and art unit 1654. Her record covers 682 resolved cases, an allowance rate of 59.8%, and a median of 973 days to allowance. The allowance rate indicates that allowance occurred in a majority of resolved matters, while the median shows prosecution extending beyond a short examination cycle.
The interview lift is 71.0%, the strongest positive interview association in this profile. Practitioners may give interviews substantial attention when planning responses, while tying any proposed amendment to a clear explanation in the written record. The listed companies are The Regents of the University of California, Nuritas Limited, and Rochal Technologies LLC. The associated firms are SUGHRUE MION, PLLC, BALLARD SPAHR LLP, and Casimir Jones, S.C.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18258636 | COMPOSITIONS COMPRISING CYCLOTIDES AND OTHER INSECTICIDAL PEPTIDES AND USES THEREOF | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18570390 | Rippled Antiparallel Cross-Beta Dimers and Related Materials, Compositions and Methods | Non-Final OA | The Regents of the University of California |
| 17980961 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | Final Rejection | The Regents of the University of California |
| 18574671 | PEPTIDE HAVING ANTICANCER ACTIVITY, AND USE THEREOF | Non-Final OA | Korea University Research and Business Foundation |
| 17599211 | USE OF CYCLO(HIS-PRO) (CHP) FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17184400 | FRACTURE TARGETED BONE REGENERATION THROUGH PARATHYROID HORMONE RECEPTOR STIMULATION | Non-Final OA | Purdue Research Foundation |
| 17917790 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LUNG DISEASE | Final Rejection | Arizona Board of Regents on Behalf of the University of Arizona |
| 18038588 | COMPOSITIONS AND METHODS OF INHIBITING THE BINDING OF PLASMA IGG AUTOANTIBODIES TO SEROTONIN 2A RECEPTOR | Final Rejection | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18294498 | VIMENTIN TARGETED PEPTOIDS FOR EARLY DIAGNOSIS AND TREATMENT OF CANCER | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
| 18004125 | THERAPEUTIC NUCLEIC ACIDS, PEPTIDES AND USES II | Final Rejection | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 17615857 | LIPIDATED CATIONIC PEPTIDE-PEG COMPOSITIONS FOR NUCLEIC ACID DELIVERY | Final Rejection | Medici Therapeutics, Inc. |
| 18570198 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE | Non-Final OA | KYOWA HAKKO BIO CO., LTD. |
| 17617043 | DEFERRED TREATMENT OF NERVE INJURIES | Final Rejection | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.8% of resolved applications examined by Li N Komatsu were allowed (682 resolved cases), compared with 48.5% across Art Unit 1654 over the last five years.
This examiner's interview lift is +71.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Li N Komatsu took 973 days on average from filing to allowance.
Li N Komatsu examines applications in Art Unit 1654 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
